SXTP — 60 DEGREES PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1946563 ·
Last close
$1.17
Market Cap
$4.11M
52W High
$8.62
52W Low
$0.84
ADV30
65,350
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 207,898 56,798 -2,271,102 -2,264,526 4,282,694 1,022,606 1,754,271
Mar 2026 162,092 76,377 -2,094,961 -2,089,214 6,763,346 3,337,760 2,018,867
Dec 2025 303,385 182,703 -1,917,351 -1,438,559 5,366,211 1,510,065 1,986,795
Sep 2025 437,602 -100,088 -2,325,525 -2,316,324 6,689,344 4,115,779 2,342,386

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,993,215
Investing CF
$-254,042
Financing CF
$8,110,544
CapEx
$-254,042
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.05
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-49,982,329
Inventory
$910,603
Receivables
$335,836
ST Investments
$0
EBIT TTM
$-7,573,838
Pretax Income TTM
$-7,581,242
Interest Exp TTM
$7,404
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,214,931
EBITDA
$-8,504,303
Free Cash Flow
$-6,081,180
Enterprise Value
$11,775,539
Total Cash
$1,022,606
Total Debt
$151,179
Shares Out
3,516,988
Trailing EPS
$-2.67
Book Value
$-2.62
ROE
-332.9%
ROA
-127.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,005,471 -7,758,579 -7,365,158 5,366,211 1,986,795 3,463,177 -6,849,022
Dec 2024 607,574 -9,715,181 -7,947,107 5,759,345 1,804,339 4,035,600 -5,648,088
Dec 2023 253,573 -5,154,583 -3,765,702 7,783,771 2,985,675 4,870,134 -4,542,910
Dec 2022 223,208 -1,750,445 -6,181,720 1,297,206 25,446,266 -23,576,740 -1,009,980

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.58

Peers — same industry

TickerNameMarket CapLastDaily %
CVKD Cadrenal Therapeutics, Inc. $4.10M $1.15 —
ERNA Ernexa Therapeutics Inc. $4.02M $3.45 —
LABT Lakewood-Amedex Biotherapeutics Inc. $3.96M $1.67 —
GRI GRI Bio, Inc. $4.48M $2.05 —
ONCO Onconetix, Inc. $4.51M $1.03 —

News headlines (Yahoo Finance, 1h cache)

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
2026-08-14 19:47 · Yahoo
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
2026-07-08 12:01 · Yahoo
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
2026-07-01 12:02 · Yahoo
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
2026-05-26 12:02 · Yahoo
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
2026-04-03 16:00 · Yahoo
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
2026-04-15 12:02 · Yahoo
Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-04-02 13:00 · Yahoo
60 Degrees Pharmaceuticals Announces 2025 Annual Results
2026-03-31 11:01 · Yahoo
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
2026-08-11 00:05 · Yahoo
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
2026-08-06 11:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.